SFE2003 Poster Presentations Endocrine tumours and neoplasia (13 abstracts)
Department of Endocrinology, Nuclear medicine and Radiology, St. Bartholomew's Hospital, Queen Mary University of London, London EC1A 7BE, UK.
THE SENSITIVITY OF 123I-MIBG IN THE DETECTION OF HISTOLOGICALLY CONFIRMED CATECHOLAMINE-PRODUCING TUMOURS.
M Ismail, R Foley, WM Drake, AB Grossman, PJ Jenkins, SL Chew, GM
Besser, R Reznek, K Britton, JP Monson
Departments of Endocrinology, Nuclear Medicine and Radiology, St
Bartholomew's Hospital (QMUL), London EC1A 7BE
Radionuclide imaging is widely used for the localization of
catecholamine-producing tumors. This is best performed with 123I-meta-iodo-
benzylguanidine (MIBG), a catecholamine (noradrenaline) analogue that utilises the amine precursor uptake mechanism and may thus be
incorporated into vesicles or neurosecretory granules in the cytoplasm. Gamma-camera images are then obtained using a low-energy collimator interfaced with a computer.
We describe a series of 31 consecutive patients presenting to our department
at St. Bartholomew's Hospital between January 1999 and April 2003 with a
diagnosis of a catecholamine-secreting tumour, elevation of urine
catecholamines and subsequent histological confirmation. 123I-MIBG
scanning was performed pre-operatively in all patients. Our series comprised
20 men (65%) and 11 women (35%); 26/31 of these tumors were primary
adrenal (84%), 3 of which were metastatic at the time of diagnosis
(11.5%); and five were extra-adrenal (16%). 123I-MIBG scanning detected 20/26 primary adrenal catecholamine-producing tumours and 3/5 extra-adrenal tumors giving a sensitivity of 77% and 60% respectively. In patients with metastatic adrenalphaeochromocytoma 123I-MIBG avidity was evident in 2 of the 3
cases.
The overall sensitivity of 123I-MIBG scanning was 74% compared with a
reported sensitivity of 80-90% in previously reported smaller series.
There was no relationship between the biochemical severity of the condition
and the presence or absence of 123I-MIBG avidity. Because our inclusion
criteria depended on histological confirmation, the sensitivity data are a reliable estimate of the yield from this localising technique. Despite the
obvious value of 123I-MIBG in confirming the nature of a radiological abnormality our
sensitivity data indicate the importance of additional cross-sectional imaging modalities in localising biochemically proven catecholamine-producing tumours.